Hyporesponsiveness to therapeutic erythropoietin has emerged as an important consequence of inflammation, especially in chronic kidney diseases [62, 63], and may be a consequence of iron restriction imposed by high hepcidin. Here, HAMP is linked to chronic kidney disease.